Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Peptides from the amino terminal mdm-2-binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells

16 Oct 2001

Abstract excerpt

We have synthesized three peptides from the mdm-2 binding domain of human p53, residues 12-26 (PPLSQETFSDLWKLL), residues 12-20, and 17-26. To enable transport of the peptides across the cell membrane and at the same time to maximize the active mdm-2 binding alpha-helical conformation for these peptides, each was attached at its carboxyl terminus to the penetratin sequence, KKWKMRRNQFWVKVQRG, that contains many...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Cancer Research and Treatments
Share to RNA modifications and cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 11606716
DOI: 10.1073/pnas.211280698

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Peptides from the amino terminal mdm-2-binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cellsPMID 11606716Read ↗

Preferential induction of necrosis in human breast cancer cells by a p53 peptide derived from the MDM2 binding site.Semantic proximity Read ↗

Sequence and helicity requirements for the proapoptotic activity of Bax BH3 peptides.Semantic proximity Read ↗

Targeting the MDM2 ‐ MDM4 interaction interface reveals an otherwise therapeutically active wild‐type p53 in colorectal cancerSemantic proximity Read ↗

Design-Rules for Stapled Alpha-Helical Peptides with On-Target In Vivo Activity: Application to Mdm2/X dual antagonistsSemantic proximity Read ↗

The effect of mutations on peptide models of the DNA binding helix of p53: evidence for a correlation between structure and tumorigenesis.Semantic proximity Read ↗

Selective induction of apoptosis through the FADD/caspase-8 pathway by a p53 c-terminal peptide in human pre-malignant and malignant cells.Semantic proximity Read ↗

The Structure‐Based Design of Mdm2/Mdmx–p53 Inhibitors Gets SeriousSemantic proximity Read ↗

Induction of human cytotoxic T lymphocytes that preferentially recognise tumour cells bearing a conformational p53 mutant.Semantic proximity Read ↗

In-Tether Chiral Center Induced Helical Peptide Modulators Target p53-MDM2/MDMX and Inhibit Tumor Growth in Stem-Like Cancer Cell.Semantic proximity Read ↗

A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines.Semantic proximity Read ↗

Characterisation of Epitopes on Human p53 using Phage-displayed Peptide Libraries: Insights into Antibody-Peptide InteractionsSemantic proximity Read ↗

Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.